Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. - Wikidata - awgldk - TriplyDB

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

http://www.wikidata.org/entity/Q37127399

about

Are we there yet? The smallpox research agenda using variola virus Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits Developments in Viral Vector-Based Vaccines.Anti-Infectious Human Vaccination in Historical Perspective.How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?

P2860

Q21131362-B59A4FE1-6441-471B-9507-BC9AB6907F9B Q30151079-AB54A992-1EED-4581-8613-F967527F6643 Q35447516-6F652D6A-BBAF-4903-AE5F-0063047AAE3E Q36057928-92B5DDBB-776F-47FE-947A-2F663FBE2F28 Q36090390-B02A2160-50B5-4C09-AE22-1FC214B9AE59 Q37135398-733ED000-0C46-42E8-BE12-5CE22A8E5587 Q38582090-341A7E10-539C-4557-96E7-274DA07496D4 Q40129444-8A6EC6F6-6A7B-42FE-8FD4-4BE16A6D929D Q41928044-00AA1091-E467-4C63-AC08-8DE2D2346048

P2860

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

http://www.wikidata.org/entity/Q37127399

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Safety and immunogenicity of I ...... ies for a post event scenario.

@en

Safety and immunogenicity of I ...... ies for a post event scenario.

@nl

type

label

Safety and immunogenicity of I ...... ies for a post event scenario.

@en

Safety and immunogenicity of I ...... ies for a post event scenario.

@nl

prefLabel

Safety and immunogenicity of I ...... ies for a post event scenario.

@en

Safety and immunogenicity of I ...... ies for a post event scenario.

@nl

P1433

Q37127399-DDC3BAE1-734E-4DF0-A9FC-B9585A7A15C5

P1476

Q37127399-14B2856E-6A1A-44BA-A4A4-4CEF32C711F7

P2093

Q37127399-0DD5AB7F-8EDC-41BF-8250-5EAB5E50388C

Q37127399-3429D657-C4BD-4832-BC0C-663C5F7C4139

Q37127399-5EAA32FE-B113-4A61-AD02-5548912906A1

Q37127399-79E6E439-419A-4D2F-A851-4C5B1DEAF1EE

Q37127399-879C1D8C-7679-4B01-8E18-08DA1682BBB7

Q37127399-AC2D3BE4-1E01-48D0-B26C-E71D22F94550

Q37127399-AE53A5E9-E90E-4220-913E-822D67294C73

Q37127399-C83D90D5-FC9D-447D-9F46-D1E59FE4F424

Q37127399-DB9CAFE8-7CD3-45C7-8F00-35FC47DD97FF

Q37127399-DED23768-6021-4D15-A7B4-920D39677831

P2860

Q37127399-0189A314-774C-4F4F-8BDA-6A31A717D27D

Q37127399-152B8042-84A4-4EF7-8E32-ADC511BAB946

Q37127399-2E24D7AD-D4DD-43F1-924C-4E5A0529EDE7

Q37127399-5545B0A9-39EE-46C3-BCEF-0570C2403FE5

Q37127399-708DA93D-3FFA-45E8-A99A-7DD2D240368C

Q37127399-834CE685-DF05-4054-B557-DF7B4D3A5F76

Q37127399-940675FF-5AA4-460B-B12C-51BF6391B022

Q37127399-B79F872C-9115-454D-95C9-E9C5DA43FDF1

Q37127399-BAD9EBF8-5615-430D-BBA6-AA52662F6A85

Q37127399-BB611500-0C33-4FB4-8B85-7B66F3237E09

P304

Q37127399-139B73C5-E95C-4862-BF28-A648BF8F2BA0

P31

Q37127399-2F30A26E-6C43-42A1-9AB2-82A7D36742FC

P356

Q37127399-50B35CFE-24E0-4E48-8EB7-0E019909A08E

P407

Q37127399-E30FF010-F5B9-4BDF-A04A-9FD7E112EBF6

P433

Q37127399-3EA0A13C-66A9-452A-A032-37E803F9499F

P478

Q37127399-7C59DC77-242A-4932-9A1B-1D24FE721333

P50

Q37127399-7CB3EE5F-68DB-41A6-9464-002EF3D5FA34

P577

Q37127399-5232E02A-2426-47E7-85ED-C3FE9DCE3CA5

P698

Q37127399-EF3E98E6-0137-4AE9-88D8-E21330101820

P921

Q37127399-611113B8-CEF7-4F5D-8768-DE769199D58A

P932

Q37127399-5065CEB4-79D3-42F5-9C2E-D5863A38B78C

P356

J.VACCINE.2013.04.050

P1433

P1476

Safety and immunogenicity of I ...... ies for a post event scenario.

@en

P2093

Christine B Turley

http://www.w3.org/2001/XMLSchema#string

Christine Mhorag Hay

http://www.w3.org/2001/XMLSchema#string

Emmanuel B Walter

http://www.w3.org/2001/XMLSchema#string

Frances K Newman

http://www.w3.org/2001/XMLSchema#string

Heather R Hill

http://www.w3.org/2001/XMLSchema#string

Magdalena Tary-Lehmann

http://www.w3.org/2001/XMLSchema#string

Paul Chaplin

http://www.w3.org/2001/XMLSchema#string

Robert A Salata

http://www.w3.org/2001/XMLSchema#string

Robert B Belshe

http://www.w3.org/2001/XMLSchema#string

Samer S El-Kamary

http://www.w3.org/2001/XMLSchema#string

P2860

ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.

The looming threat of bioterrorism.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Evaluation of smallpox vaccines using variola neutralization.

Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.

Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Vaccines in civilian defense against bioterrorism.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

P304

3025-3033

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2013.04.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Patricia L Winokur

P577

2013-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23664987

http://www.w3.org/2001/XMLSchema#string

P921

P932

3755481

http://www.w3.org/2001/XMLSchema#string